VIROSTOP
11.11.2021 12:02:13 CET | Business Wire | Press release
A recent clinical study has shown that the ViroStop nose and throat spray can have a preventative effect against Covid-19 infection, while at the same time boosting the body’s antibody response to the virus. The results support the findings of laboratory tests and an earlier study which also showed the product’s ability to reduce viral shedding and thereby slow the spread of the disease.
Volunteers in the study were all close contacts of someone with a positive PCR test for Covid-19. Out of 189 people 111 used ViroStop and a control group of 78 did not. After 15 days not one of the volunteers using ViroStop gave a positive PCR test while six (roughly 8%) of the control group did. Furthermore, in blood antibody tests, those who took ViroStop were seen to develop immunological protection against Covid-19 in three times more cases than the control group.
Dr István Jankovics, whose team ran the study at Budapest’s Complex Medical Clinic between January and May 2021, commented: “The study confirms our in-vitro (laboratory) tests that ViroStop not only reduces the spread of the virus but can actually help prevent infection in the first place.
The improved immunological response among those with a negative PCR test suggests that the spray reduced the amount of virus in volunteers to such an extent that it could not be detected by PCR but the immune system recognized the virus and produced the specific antibody in response.”
Leading UK expert in primary care, Professor James Kingsland commented: “This is an encouraging development and anything that shows evidence of an additional layer of protection is to be welcomed. The virus is now endemic and rates of infection are still far too high. The best defence is vaccination but anti-viral sprays such as ViroStop can be a useful addition to mask wearing in crowded spaces, social distancing and hand washing.”
The retrospective study took place at the Complex Medical Clinic in Budapest, Hungary between January 15th , and May 31st , 2021 and the results were published in the American publication: Journal of Community Medicine and Public Health Reports. In study of clinical, virological and serological data from patients with mild acute upper respiratory tract infections, a total of 189 volunteers participated. All of the volunteers were close contacts of a COVID-19 PCR positive patient with mild symptoms. Of the 189 individuals, 111 used Virostop after positive PCR analysis of their contact, while 78 did not. All volunteers were tested by PCR assays for SARS CoV-2 at the beginning of the study, and symptoms of each volunteer were checked every two days for 15 days. At the end of the clinical study, each participant underwent a PCR test again for SARS CoV-2, and also a SARS CoV-2 specific IgG antibody assay using the ELISA system, then the symptoms of volunteers were evaluated.
ViroStop made by Swiss company, Herb-Pharma AG comes in the form of a nasal and oral spray. Its patented mix of active and natural ingredients act as a barrier against infections and can also alleviate the symptoms of flu and colds. The anti-viral sprays create a protective film on the mucous membrane in the upper respiratory tract to neutralize viruses and prevent multiplication.
For more information visit ViroStop website. The nasal and oral sprays are available online at Stressnomore.co.uk and can also be purchased at fytofontana.com .
ENDS
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005256/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom